Plexus stock price target lowered to $140 by Stifel on mixed outlook

Plexus (PLXS) reported fiscal Q3 2025 EPS of $1.90, exceeding consensus estimates of $1.71 primarily due to lower interest expenses and favorable tax adjustments, despite sales of $1.018 billion slightly missing expectations. Stifel maintained a Hold rating but reduced its price target to $140 from $145, citing mixed Q4 guidance where the EPS midpoint slightly exceeds but the sales midpoint falls below analyst expectations. The company anticipates continued near-term pressure in Industrial and Aerospace OEMs, though Defense remains a bright spot and Healthcare/Life Sciences shows future growth potential, contributing to the stock's nearly 15% decline over the past week.

Analysis

Plexus Corp. (PLXS) presented a mixed operational and financial picture for its fiscal third quarter of 2025, triggering a cautious analyst revision and significant negative pressure on its stock, which fell nearly 15% over the past week. The company reported earnings per share of $1.90, a notable 11.11% beat over the $1.71 consensus estimate. However, this outperformance was largely technical, attributed to lower interest expenses and a favorable tax adjustment rather than core operational strength. This is underscored by the top-line performance, where revenue of $1.018 billion was only in-line and slightly missed the $1.02 billion consensus. The forward-looking guidance further fueled investor concern; while the Q4 adjusted EPS midpoint of $1.90 is slightly above consensus, the sales midpoint guidance fell approximately 3.7% below analyst expectations. In response, Stifel maintained its Hold rating but cut its price target to $140 from $145, citing continued near-term pressure in the Industrial and Aerospace OEM segments into fiscal 2026. Despite these headwinds and limited visibility in the Healthcare/Life Sciences segment, the company's fundamentals appear robust, as evidenced by a perfect Piotroski Score of 9, indicating strong financial health.

Key Decisions for Investors

• Investors should prioritize monitoring top-line revenue trends over bottom-line earnings, as the recent EPS beat was driven by non-operational items and is overshadowed by a weak forward sales forecast.
• The current Hold rating from Stifel appears justified given the conflict between a weak near-term sales outlook and the company's strong underlying financial health, indicated by its perfect Piotroski Score.
• Given the stock's recent 15% decline on negative sentiment, investors should watch for signs of stabilization or recovery in the Industrial and Aerospace OEM segments before considering a new position, as these are cited as key areas of near-term pressure.